Bionexus Gene La Financials

BGLC

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Bionexus Gene La (BGLC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BGLC FY2025 2026-05-15

Falling revenue has left thin gross profit unable to absorb overhead, even as the company remains lightly leveraged.

A financing inflow of $6.27M in FY2023 pushed cash up to $4.52M. By FY2025, cash had slipped to $2.49M after roughly $1.8M of annual operating outflow, so the balance sheet's cushion came from external funding rather than the business turning profit into cash.

Gross margin edged up to 14.6% in FY2025 from 13.6% in FY2024. But operating margin fell to -39.9%, which suggests the core issue is fixed-cost absorption: SG&A has been larger than gross profit for three straight years, so a smaller sales base is carrying too much overhead.

Liquidity looks comfortable on paper because the current ratio reached 10.5x and total liabilities were only $638K. That points to an equity-funded balance sheet with little solvency pressure, while lower receivables and inventory suggest management has been shrinking the working-capital footprint to preserve cash.

Financial Health Signals

Financial Health Score 52/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Bionexus Gene La's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Safe

3.12

Bionexus Gene La scores 3.12, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.9M) relative to total liabilities ($638K). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Bionexus Gene La passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.62x

For every $1 of reported earnings, Bionexus Gene La generates $0.62 in operating cash flow (-$1.8M OCF vs -$3.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$7.4M

YoY-21.9%

5Y CAGR-8.2%

Bionexus Gene La generated $7.4M in revenue in fiscal year 2025. This represents a decrease of 21.9% from the prior year.

EBITDA

-$2.9M

YoY-100.8%

Bionexus Gene La's EBITDA was -$2.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 100.8% from the prior year.

Net Income

-$3.0M

YoY-86.7%

Bionexus Gene La reported -$3.0M in net income in fiscal year 2025. This represents a decrease of 86.7% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

-$1.9M

YoY+19.2%

Bionexus Gene La generated -$1.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 19.2% from the prior year.

Cash & Debt

$2.5M

YoY-13.9%

5Y CAGR-2.3%

Bionexus Gene La held $2.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Bionexus Gene La had 2M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

14.6%

YoY+1.1pp

5Y CAGR-0.5pp

Bionexus Gene La's gross margin was 14.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.1 percentage points from the prior year.

Operating Margin

-39.9%

YoY-23.4pp

5Y CAGR-51.1pp

Bionexus Gene La's operating margin was -39.9% in fiscal year 2025, reflecting core business profitability. This is down 23.4 percentage points from the prior year.

Net Margin

-40.2%

YoY-23.4pp

5Y CAGR-49.8pp

Bionexus Gene La's net profit margin was -40.2% in fiscal year 2025, showing the share of revenue converted to profit. This is down 23.4 percentage points from the prior year.

Return on Equity

-34.6%

YoY-15.4pp

5Y CAGR-51.1pp

Bionexus Gene La's ROE was -34.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 15.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$51K

YoY+6.6%

Bionexus Gene La invested $51K in research and development in fiscal year 2025. This represents an increase of 6.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$37K

YoY-83.7%

5Y CAGR-38.5%

Bionexus Gene La invested $37K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 83.7% from the prior year.

BGLC Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$7.4M-21.9%	$9.5M-2.7%	$9.8M-10.6%	$10.9M-18.2%	$13.4M+17.3%	$11.4M
Cost of Revenue	$6.3M-22.9%	$8.2M-2.6%	$8.4M-12.7%	$9.7M-12.9%	$11.1M+14.7%	$9.7M
Gross Profit	$1.1M-15.8%	$1.3M-3.0%	$1.3M+5.6%	$1.3M-44.5%	$2.3M+31.8%	$1.7M
R&D Expenses	$51K+6.6%	$48K-13.6%	$55K	N/A	N/A	N/A
SG&A Expenses	$1.5M-16.2%	$1.8M-25.0%	$2.4M+41.2%	$1.7M+35.4%	$1.3M-4.2%	$1.3M
Operating Income	-$3.0M-88.4%	-$1.6M+39.3%	-$2.6M-790.7%	-$291K-127.6%	$1.1M-17.1%	$1.3M
Interest Expense	N/A	N/A	$14K+11.6%	$12K	N/A	N/A
Income Tax	$0+100.0%	-$3K+83.8%	-$22K+58.8%	-$52K+82.0%	-$291K	N/A
Net Income	-$3.0M-86.7%	-$1.6M+39.2%	-$2.6M-638.6%	-$356K-147.4%	$752K-31.3%	$1.1M
EPS (Diluted)	N/A	$-0.09+45.8%	$-0.17	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$23K-95.3%	$484K-81.0%	$2.5M+12.5%	$2.3M+5.8%	$2.1M-15.3%	$2.5M-4.0%	$2.6M+33.2%	$2.0M
Cost of Revenue	$24K-95.2%	$488K-77.5%	$2.2M+14.5%	$1.9M+5.5%	$1.8M-19.0%	$2.2M-3.9%	$2.3M+36.7%	$1.7M
Gross Profit	-$790+80.2%	-$4K-101.1%	$378K+2.6%	$368K+7.1%	$343K+11.1%	$309K-5.3%	$327K+13.1%	$289K
R&D Expenses	$14K+30.5%	$11K-25.4%	$15K+18.5%	$13K+3.4%	$12K-30.2%	$17K+66.6%	$10K+27.4%	$8K
SG&A Expenses	$328K+80.9%	$181K-59.4%	$446K-13.8%	$517K+31.9%	$392K+136.2%	$166K-79.1%	$792K+41.8%	$559K
Operating Income	-$540K+47.7%	-$1.0M-47.0%	-$703K-14.9%	-$611K+1.2%	-$618K-48.6%	-$416K+68.9%	-$1.3M-616.1%	$259K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	$6K	N/A
Income Tax	$0	$0	$0	$0	$0+100.0%	-$41K-2708.7%	$2K-97.2%	$56K
Net Income	-$544K+47.5%	-$1.0M-46.1%	-$709K-15.1%	-$616K+1.1%	-$623K-79.0%	-$348K+74.1%	-$1.3M-775.7%	$199K
EPS (Diluted)	$-0.23	N/A	$-0.40-15.2%	$-0.34+1.2%	$-0.35	N/A	$-0.75-762.8%	$0.11

BGLC Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$9.3M-11.3%	$10.4M-8.5%	$11.4M+30.4%	$8.7M-8.7%	$9.6M-5.3%	$10.1M
Current Assets	$5.4M-26.7%	$7.4M-7.7%	$8.0M+33.6%	$6.0M-15.8%	$7.1M-10.5%	$8.0M
Cash & Equivalents	$2.5M-13.9%	$2.9M-36.1%	$4.5M+113.2%	$2.1M-0.2%	$2.1M-23.8%	$2.8M
Inventory	$677K-51.3%	$1.4M+22.0%	$1.1M+16.4%	$978K-35.8%	$1.5M+29.4%	$1.2M
Accounts Receivable	$506K-63.3%	$1.4M+72.1%	$800K-72.1%	$2.9M-14.6%	$3.4M	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$638K-69.8%	$2.1M+21.2%	$1.7M-16.1%	$2.1M-13.3%	$2.4M-30.7%	$3.5M
Current Liabilities	$521K-73.3%	$2.0M+19.6%	$1.6M-18.6%	$2.0M-13.9%	$2.3M-31.0%	$3.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.6M+3.5%	$8.3M-13.8%	$9.7M+44.9%	$6.7M-7.2%	$7.2M+7.8%	$6.7M
Retained Earnings	-$6.4M-86.7%	-$3.4M-86.7%	-$1.8M-259.5%	$1.2M-23.5%	$1.5M+98.8%	$761K

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$9.0M-2.3%	$9.3M+21.4%	$7.6M-19.1%	$9.4M-0.6%	$9.5M-9.1%	$10.4M-5.1%	$11.0M-1.3%	$11.1M
Current Assets	$5.2M-4.6%	$5.4M-3.2%	$5.6M-11.8%	$6.4M-2.5%	$6.5M-12.0%	$7.4M+5.6%	$7.0M-10.2%	$7.8M
Cash & Equivalents	$1.3M-46.2%	$2.5M+115.6%	$1.2M+41.6%	$814K-61.0%	$2.1M-27.6%	$2.9M-30.2%	$4.1M-23.6%	$5.4M
Inventory	$667K-1.4%	$677K-32.8%	$1.0M-17.1%	$1.2M+3.1%	$1.2M-15.1%	$1.4M0.0%	$1.4M+34.5%	$1.0M
Accounts Receivable	$80K-84.2%	$506K-66.8%	$1.5M-17.8%	$1.9M+28.4%	$1.4M+4.8%	$1.4M-3.4%	$1.4M+44.3%	$988K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$947K+48.4%	$638K-20.8%	$805K-57.6%	$1.9M+11.2%	$1.7M-19.1%	$2.1M+31.4%	$1.6M+0.8%	$1.6M
Current Liabilities	$796K+52.9%	$521K-23.2%	$678K-61.4%	$1.8M+12.7%	$1.6M-20.0%	$2.0M+37.9%	$1.4M+1.1%	$1.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$8.1M-6.1%	$8.6M+26.4%	$6.8M-9.4%	$7.5M-3.2%	$7.8M-6.6%	$8.3M-11.3%	$9.4M-1.7%	$9.5M
Retained Earnings	-$7.0M-8.5%	-$6.4M-19.2%	-$5.4M-15.1%	-$4.7M-15.2%	-$4.1M-18.1%	-$3.4M-11.3%	-$3.1M-76.9%	-$1.7M

BGLC Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$1.8M+12.2%	-$2.1M-14.9%	-$1.8M-430.2%	$552K+5923.6%	$9K-98.3%	$553K
Capital Expenditures	$37K-83.7%	$227K+51.9%	$149K	$0-100.0%	$3K-99.3%	$422K
Free Cash Flow	-$1.9M+19.2%	-$2.3M-17.7%	-$2.0M-457.3%	$552K+9098.6%	$6K-95.4%	$131K
Investing Cash Flow	$945K+125.9%	$418K+123.3%	-$1.8M-298.3%	-$450K+8.2%	-$491K-137.2%	$1.3M
Financing Cash Flow	$299K+7418.0%	$4K-99.9%	$6.3M+5701.1%	$108K+483.3%	-$28K-470.5%	-$5K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$148K-115.4%	$961K+177.7%	-$1.2M-67.7%	-$738K+10.5%	-$824K-475.9%	$219K+113.7%	-$1.6M-138.4%	-$672K
Capital Expenditures	$325-66.7%	$977-82.2%	$5K-74.4%	$21K+137.1%	$9K+125.1%	$4K-98.0%	$199K+10766.8%	$2K
Free Cash Flow	-$148K-115.4%	$960K+177.2%	-$1.2M-63.7%	-$759K+8.9%	-$833K-487.2%	$215K+111.9%	-$1.8M-167.3%	-$674K
Investing Cash Flow	-$14K-144.7%	-$6K-100.6%	$995K+3586.1%	-$29K-82.4%	-$16K-102.8%	$554K+372.9%	-$203K-420.9%	$63K
Financing Cash Flow	$60K-77.6%	$267K+679.7%	$34K+3419.1%	-$1K-19.8%	-$860+99.4%	-$142K-154.3%	-$56K-131.9%	$175K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BGLC Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	14.6%+1.1pp	13.6%-0.1pp	13.6%+2.1pp	11.5%-5.4pp	17.0%+1.9pp	15.1%
Operating Margin	-39.9%-23.4pp	-16.6%+10.0pp	-26.5%-23.9pp	-2.7%-10.6pp	7.9%-3.3pp	11.2%
Net Margin	-40.2%-23.4pp	-16.8%+10.1pp	-26.9%-23.7pp	-3.3%-8.9pp	5.6%-4.0pp	9.6%
Return on Equity	-34.6%-15.4pp	-19.2%+8.0pp	-27.2%-21.9pp	-5.3%-15.8pp	10.5%-6.0pp	16.4%
Return on Assets	-32.3%-16.9pp	-15.3%+7.7pp	-23.1%-19.0pp	-4.1%-11.9pp	7.8%-3.0pp	10.8%
Current Ratio	10.46+6.7	3.81-1.1	4.93+1.9	3.00-0.1	3.07+0.7	2.37
Debt-to-Equity	0.07-0.2	0.25+0.1	0.18-0.1	0.31-0.0	0.33-0.2	0.52
FCF Margin	-25.3%-0.9pp	-24.4%-4.2pp	-20.2%-25.2pp	5.1%+5.0pp	0.0%-1.1pp	1.1%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	-3.5%-2.6pp	-0.8%-15.7pp	14.8%-1.4pp	16.3%+0.2pp	16.1%+3.8pp	12.3%-0.2pp	12.4%-2.2pp	14.6%
Operating Margin	-2366.2%-2152.7pp	-213.5%-185.9pp	-27.6%-0.6pp	-27.1%+1.9pp	-28.9%-12.4pp	-16.5%+34.4pp	-50.8%-64.0pp	13.1%
Net Margin	-2379.7%-2165.5pp	-214.2%-186.3pp	-27.9%-0.6pp	-27.3%+1.9pp	-29.2%-15.4pp	-13.8%+37.3pp	-51.1%-61.2pp	10.1%
Return on Equity	-6.7%+5.3pp	-12.0%-1.6pp	-10.4%-2.2pp	-8.2%-0.2pp	-8.0%-3.8pp	-4.2%+10.1pp	-14.3%-16.4pp	2.1%
Return on Assets	-6.0%+5.2pp	-11.2%-1.9pp	-9.3%-2.8pp	-6.5%+0.0pp	-6.6%-3.2pp	-3.3%+8.9pp	-12.2%-14.0pp	1.8%
Current Ratio	6.52-3.9	10.46+2.2	8.30+4.7	3.63-0.6	4.19+0.4	3.81-1.2	4.98-0.6	5.60
Debt-to-Equity	0.12+0.0	0.07-0.0	0.12-0.1	0.25+0.0	0.22-0.0	0.25+0.1	0.170.0	0.17
FCF Margin	-647.9%-846.4pp	198.5%+247.3pp	-48.9%-15.3pp	-33.6%+5.4pp	-39.0%-47.5pp	8.5%+77.1pp	-68.5%-34.4pp	-34.1%

Similar Companies

Cn Energy Group Inc CNEY

$5.2M

Bolt Projects Holdings Inc BSLK

$2.5M

Bon Natural Life Ltd BON

$9.4M

Senestech Inc SNES

$7.5M

Northern Techn NTIC

$76.1M

Frequently Asked Questions

What is Bionexus Gene La's annual revenue?

Bionexus Gene La (BGLC) reported $7.4M in total revenue for fiscal year 2025. This represents a -21.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bionexus Gene La's revenue growing?

Bionexus Gene La (BGLC) revenue declined by 21.9% year-over-year, from $9.5M to $7.4M in fiscal year 2025.

Is Bionexus Gene La profitable?

No, Bionexus Gene La (BGLC) reported a net income of -$3.0M in fiscal year 2025, with a net profit margin of -40.2%.

What is Bionexus Gene La's EBITDA?

Bionexus Gene La (BGLC) had EBITDA of -$2.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Bionexus Gene La's gross margin?

Bionexus Gene La (BGLC) had a gross margin of 14.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Bionexus Gene La's operating margin?

Bionexus Gene La (BGLC) had an operating margin of -39.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Bionexus Gene La's net profit margin?

Bionexus Gene La (BGLC) had a net profit margin of -40.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Bionexus Gene La's return on equity (ROE)?

Bionexus Gene La (BGLC) has a return on equity of -34.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bionexus Gene La's free cash flow?

Bionexus Gene La (BGLC) generated -$1.9M in free cash flow during fiscal year 2025. This represents a 19.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bionexus Gene La's operating cash flow?

Bionexus Gene La (BGLC) generated -$1.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bionexus Gene La's total assets?

Bionexus Gene La (BGLC) had $9.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Bionexus Gene La's capital expenditures?

Bionexus Gene La (BGLC) invested $37K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Bionexus Gene La spend on research and development?

Bionexus Gene La (BGLC) invested $51K in research and development during fiscal year 2025.

How many shares does Bionexus Gene La have outstanding?

Bionexus Gene La (BGLC) had 2M shares outstanding as of fiscal year 2025.

What is Bionexus Gene La's current ratio?

Bionexus Gene La (BGLC) had a current ratio of 10.46 as of fiscal year 2025, which is generally considered healthy.

What is Bionexus Gene La's debt-to-equity ratio?

Bionexus Gene La (BGLC) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bionexus Gene La's return on assets (ROA)?

Bionexus Gene La (BGLC) had a return on assets of -32.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bionexus Gene La's cash runway?

Based on fiscal year 2025 data, Bionexus Gene La (BGLC) had $2.5M in cash against an annual operating cash burn of $1.8M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Bionexus Gene La's Altman Z-Score?

Bionexus Gene La (BGLC) has an Altman Z-Score of 3.12, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Bionexus Gene La's Piotroski F-Score?

Bionexus Gene La (BGLC) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bionexus Gene La's earnings high quality?

Bionexus Gene La (BGLC) has an earnings quality ratio of 0.62x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Bionexus Gene La?

Bionexus Gene La (BGLC) scores 52 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.